María Sanjurjo Sáez-rekin lankidetzan egindako argitalpenak (8)

2023

  1. Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study

    Pharmacological Reports, Vol. 75, Núm. 5, pp. 1254-1264

2022

  1. Dolutegravir-Based Dual Therapies in HIV Pretreated Patients: A Real-Life Study in Madrid

    Annals of Pharmacotherapy, Vol. 56, Núm. 4, pp. 401-411

  2. Implementation and evaluation of a home pharmaceutical care model through Telepharmacy

    Farmacia Hospitalaria, Vol. 46, pp. 36-46

2020

  1. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients

    Annals of Pharmacotherapy, Vol. 54, Núm. 7, pp. 633-643

  2. Topical Administration of Amphotericin B as an Effective Adjuvant Treatment for a Deep Fungal Infection of Diabetic Foot Injury

    American journal of therapeutics, Vol. 27, Núm. 6, pp. e670-e671

2018

  1. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients

    Annals of Pharmacotherapy, Vol. 52, Núm. 1, pp. 11-18

  2. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study

    Expert Opinion on Drug Safety, Vol. 17, Núm. 3, pp. 235-241

2017

  1. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks

    International Journal of Clinical Practice, Vol. 71, Núm. 8